. . "approved"@en . . . . . . . . . . "Octrotide"@en . "Octreotide binds to somatostatin receptors. These receptors are coupled via pertussis toxin sensitive G proteins which lead to inhibition of adenylyl cyclase. Octreotide binding to these receptors also stimulates phosphotyrosine phosphatase and activation of the Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins."@en . . . "Octreotidum"@en . . "investigational"@en . . . . . . "About 32% of the dose is excreted unchanged into the urine."@en . "Octreotida"@en . "* 7 \u2013 10 L/hr [healthy after 100-mcg SC injection] * 18 L/hr [patients with acromegaly after 100-mcg SC injection] * 8.8 L/hr [mild renal impairment after 100-mcg SC injection] * 7.3 L/hr [moderate renal impairment after 100-mcg SC injection] * 7.6 L/hr [severe renal impairment after 100-mcg SC injection] * 4.5 L/hr [severe renal failure requiring dialysis after 100-mcg SC injection] * 5.9 L/hr [Patients with liver cirrhosis after 100-mcg SC injection] * 8.2 L/hr [patients with fatty liver disease after 100-mcg SC injection]"@en . . . . . . "Nishith Chaturvedi, \"Novel process for production of the somatostatin analog, octreotide.\" U.S. Patent US20040225108, issued November 11, 2004."@en . . . . . . . . . . . . . . . "Humans and other mammals"@en . . . . . . . . . . . . . " "@en . . . "Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin."@en . . . . . . . . . . " "@en . "For treatment of acromegaly and reduction of side effects from cancer chemotherapy"@en . . . . . . . . . . . . . . . . . "# Uhl W, Anghelacopoulos SE, Friess H, Buchler MW: The role of octreotide and somatostatin in acute and chronic pancreatitis. Digestion. 1999;60 Suppl 2:23-31. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10207228"@en . . . . "Octreotide"@en . . . . . "83150-76-9"@en . . "* 13.6 L [healthy volunteers] * 21.6\u00B18.5 L [patients with acromegaly]"@en . . . . . . . .